# Henagliflozin in Patients With Atrial Fibrillation

> **NCT05252624** · PHASE3 · UNKNOWN · sponsor: **Beijing Anzhen Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** placebo
- **DRUG:** Henagliflozin 5Mg Tab

## Key facts

- **NCT ID:** NCT05252624
- **Lead sponsor:** Beijing Anzhen Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-01
- **Primary completion:** 2023-09-30
- **Final completion:** 2023-09-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05252624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05252624, "Henagliflozin in Patients With Atrial Fibrillation". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05252624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*